Compare Futu Holdings Ltd (FUTU) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Revvity Inc — how do they compare? Futu Holdings Ltd trades at $111.07 (market cap $15.25B), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Futu Holdings Ltd and Revvity Inc are close in size by market cap, and Futu Holdings Ltd pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Revvity Inc for 12 Days on average.
| FUTU | RVTY | |
|---|---|---|
Market Cap | $15.25B | $16.98B |
Volume | 812,567 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $199.04 | $157.36 |
52-Week Low | $89.76 | $82.26 |
Typical Hold Time | 34 Days | 12 Days |
Enterprise Value | $15.59B | $19.30B |
Dividend Yield | 2.39% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings trades at $109.68, down 3.12% today amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.86, net income margin of 42.92%, and robust revenue growth from $13.6B in 2024 to $22.85B in 2025. Recent news includes Moomoo's partnership with X's Cashtag program and a class action lawsuit deadline on August 25, 2026.
The outlook is mixed: strong profitability and analyst upside targets near 33% contrast with legal risks and technical weakness. Key risks include lawsuit outcomes and market volatility, while growth drivers are overseas expansion and trading platform adoption. Investors face a balance of high returns potential against significant headline risks.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
